COLINZ LABORATORIES LTD.

Saffron Capital Advisors Pvt Ltd, acting as the Manager to the Open Offer, has submitted a Draft Letter of Offer (DLOF) to BSE. The open offer is being made by Antariksh Dugar (Acquirer 3), along with Annjana Dugar (Acquirer 1), Likhitta Dugar (Acquirer 2), and Padam Dugar (PAC), to acquire up to 6,54,966 equity shares of Colinz Laboratories Ltd. This represents 26% of the voting share capital. The offer price is ₹54 per equity share, valuing the total acquisition at ₹3,53,68,164. The offer is being made pursuant to SEBI (SAST) Regulations, 2011, for substantial acquisition of shares and voting rights accompanied by a change in control, and is not conditional on minimum acceptance.

Colinz Laboratories Limited has informed the exchange that Regulation 32 of SEBI (LODR) Regulations, 2015, pertaining to the statement of deviation or variation for proceeds of public issue, rights issue, preferential issue, or QIP, is not applicable to the company for the quarter ended June 30, 2026. This is because the company has not undertaken any such fundraising activities during the period. The disclosure is made as per regulatory requirements.

Colinz Laboratories Ltd has completed the sale of its factory undertaking, including the factory building and land located in Nashik, for an aggregate consideration of ₹4,00,00,000. The company received the second and final tranche of the sale consideration, concluding all necessary formalities. The buyer, Hilsun Private Limited, is an unrelated third party. This transaction is outside the company's Scheme of Arrangement.

Saffron Capital Advisors Private Limited, acting as the Manager to the Offer, has submitted a Detailed Public Statement to BSE regarding an open offer for Colinz Laboratories Limited. The offer aims to acquire up to 6,54,966 equity shares, representing 26% of the voting share capital, at a price of ₹54 per share. The total value of the open offer is ₹3,53,68,164. The offer is being made by Anjana Dugar, Likhiita Dugar, and Antariksh Dugar, collectively referred to as 'Acquirers', along with Padam Dugar, a 'Person Acting In Concert' (PAC). The offer is in compliance with SEBI (SAST) Regulations, 2011, and is being made to the public shareholders of Colinz Laboratories Limited. The Detailed Public Statement was published on June 25, 2026, in Financial Express, Jansatta, and Pratahkal.

Colinz Laboratories Limited has announced a significant promoter share sale. Ms. Vijaya Mani, a promoter, has executed a Share Purchase Agreement (SPA) to sell 8,70,500 equity shares, representing 34.56% of the company's total voting share capital, to Annjana Dugar, Likhitta Dugar, and Antraiksh Dugar. The transaction is valued at ₹50 per equity share, totaling approximately ₹4.35 crore. The sale is subject to certain conditions, and upon completion, the Acquirers will gain control and management rights of the company. As per SEBI regulations, the Acquirers are required to make an Open Offer to the public shareholders.

Saffron Capital Advisors Private Limited, acting as the Manager to the Offer, has announced a public open offer for Colinz Laboratories Limited. The offer aims to acquire up to 6,54,966 equity shares, representing 26% of the voting share capital, at a price of ₹54 per share. The total value of the open offer is ₹3,53,68,164. This move is in compliance with SEBI (SAST) Regulations, 2011, and involves Acquirers (Anjana Dugar, Likhitta Dugar, Antariksh Dugar) and a Person Acting in Concert (Padam Dugar), acquiring shares from a Seller (Vijaya Mani). The acquisition is based on a Share Purchase Agreement dated June 18, 2026.

Colinz Laboratories Ltd has responded to a clarification request regarding its share price movement. The company stated that it has complied with all SEBI disclosure requirements and there is no unpublished price-sensitive information. They believe the recent share price movement is purely market-driven and not influenced by any company actions. Colinz Laboratories remains committed to timely disclosure of material information.

Vijaya Mani, Promoter and Director of Colinz Laboratories Ltd, disposed of 3,78,000 equity shares of the company through an off-market transaction on May 21, 2026. This disclosure was made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Following the sale, Vijaya Mani's holding decreased from 49.56% to 34.56% of the total share capital, leaving her with 8,70,500 shares.

Colinz Laboratories Ltd has received disclosures under Regulation 29(1) and 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, on May 22, 2026. The disclosures pertain to the off-market acquisition of equity shares by Mr. Padam Dugar along with Persons Acting in Concert (PAC). The acquisition involves 314,000 equity shares.

Vijaya Mani, part of the Promoter/Promoter Group of Colinz Laboratories Ltd, disposed of 3,78,000 shares of the company in an off-market transaction on May 21, 2026. This disclosure was made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. Post-sale, Vijaya Mani's holding decreased from 49.56% to 34.56% of the total share capital.